The regression of tumors after therapeutic PD-1 blockade requires pre-existing CD8+ T cells, which are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance, suggesting that the level of tumor infiltration by CD8+ T cells may serve as a predictive indicator for the response to immunotherapy (102). Here, PDCD1 is linked to neoplasm.